Peficitinib
Peficitinib
Peficitinib (pronunciation: peh-fih-sit-in-ib) is an oral Janus kinase inhibitor used in the treatment of rheumatoid arthritis. It is developed by Astellas Pharma and is marketed under the brand name Smyraf.
Etymology
The name "Peficitinib" is derived from the drug's mechanism of action. "Pefi" is an abbreviation of "Peficitinib", "tinib" is a common suffix for kinase inhibitors, indicating the drug's function.
Mechanism of Action
Peficitinib works by inhibiting the activity of Janus kinase (JAK), a type of enzyme that plays a crucial role in the signaling pathways for various immune and inflammatory responses. By blocking JAK, Peficitinib helps to reduce inflammation and other symptoms associated with rheumatoid arthritis.
Related Terms
- Janus kinase inhibitor: A type of drug that blocks the action of Janus kinases.
- Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Astellas Pharma: A Japanese multinational pharmaceutical company, the developer of Peficitinib.
See Also
External links
- Medical encyclopedia article on Peficitinib
- Wikipedia's article - Peficitinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski